When antivirals backfire: An evaluation of favipiravir’s clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study

BACKGROUND: Favipiravir is an oral antiviral, that might treat COVID-19 by enhancing viral eradication, particularly in patients with mild-to-moderate disease. Yet, the findings on the use of favipiravir in critically ill patients with COVID-19 are inconsistent. Therefore, this study aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Sulaiman, Khalid, Aljuhani, Ohoud, Korayem, Ghazwa B., Altebainawi, Ali F., AlFaifi, Mashael, Nahari, Majed, Almagthali, Alaa, Thabit, Abrar K., Alhajaji, Raghad, Alharbi, Reham, Kahtani, Khawla, Alenazi, Abeer A., Alharbi, Aisha, Alghwainm, Munirah M., Alotaibi, Sara M., Alghamdi, Yazeed S., Alotaibi, Samar, Alonazi, Shaden H., Almutairi, Jumanah M., Vishwakarma, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265931/
https://www.ncbi.nlm.nih.gov/pubmed/37355406
http://dx.doi.org/10.1016/j.jiph.2023.06.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265931/
https://www.ncbi.nlm.nih.gov/pubmed/37355406
http://dx.doi.org/10.1016/j.jiph.2023.06.011

Ejemplares similares